Mostrar el registro sencillo del ítem

dc.contributor.authorBertomeu-Gonzalez, V.*
dc.contributor.authorMoreno-Arribas, J.*
dc.contributor.authorHeras, S.*
dc.contributor.authorFernandez-Ortiz, N.*
dc.contributor.authorCazorla, D.*
dc.contributor.authorQuintanilla, M.A.*
dc.contributor.authorLopez-Ayala, J.M.*
dc.contributor.authorFacila, L.*
dc.contributor.authorZuazola, P.*
dc.contributor.authorCordero, Alberto*
dc.date.accessioned2025-09-09T12:42:48Z
dc.date.available2025-09-09T12:42:48Z
dc.date.issued2023
dc.identifier.citationBertomeu-Gonzalez V, Moreno-Arribas J, Heras S, Fernandez-Ortiz N, Cazorla D, Quintanilla MA, et al. Increased Risk of Heart Failure in Elderly Patients Treated with Beta-Blockers After AV Node Ablation. American Journal of Cardiovascular Drugs. 2023;23(2):157-64.
dc.identifier.issn1179-187X
dc.identifier.otherhttps://portalcientifico.sergas.gal//documentos/63df0a766fdec82c4e7deaf6
dc.identifier.urihttp://hdl.handle.net/20.500.11940/21633
dc.description.abstractIntroduction: Controversy exists regarding the indication of beta-blockers (BB) in different scenarios in patients with cardiovascular disease. We sought to evaluate the effect of BB on survival and heart failure (HF) hospitalizations in a sample of pacemaker-dependent patients after AV node ablation to control ventricular rate for atrial tachyarrhythmias. Methods: A retrospective study including consecutive patients that underwent AV node ablation was conducted in a single center between 2011 and 2019. The study's primary endpoints were the incidence of all-cause mortality, first HF hospitalization and the cumulative incidence of subsequent hospitalizations for HF. Competing risk analyses were employed. Results: A total of 111 patients with a mean age of 73.9 years were included in the study. After a median follow-up of 45.5 months, 43 patients had died (38.7%) and 31 had been hospitalized for HF (27.9%). The recurrent HF hospitalization rate was 74/1000 patients/year. Patients treated with BB had a non-significant trend to higher mortality rates and a higher risk of recurrent HF hospitalizations (incidence rate ratio 2.23, 95% confidence interval 1.12-4.44; p = 0.023). Conclusion: After an AV node ablation, the use of BB is associated with an increased risk of HF hospitalizations in a cohort of elderly patients.
dc.description.sponsorshipOpen Access funding provided thanks to the CRUE-CSIC agreement with Springer Nature. No external funding was used in the preparation of this article
dc.languageeng
dc.rightsAttribution-NonCommercial 4.0 International (CC BY-NC 4.0)*
dc.rights.urihttp://creativecommons.org/licenses/by-nc/4.0/*
dc.subject.meshHumans *
dc.subject.meshAged *
dc.subject.meshRetrospective Studies *
dc.subject.meshAtrioventricular Node *
dc.subject.meshHeart Failure *
dc.subject.meshAdrenergic beta-Antagonists *
dc.subject.meshHeart Rate *
dc.subject.meshHospitalization *
dc.titleIncreased Risk of Heart Failure in Elderly Patients Treated with Beta-Blockers After AV Node Ablation
dc.typeArtigo
dc.authorsophosBertomeu-Gonzalez, V.; Moreno-Arribas, J.; Heras, S.; Fernandez-Ortiz, N.; Cazorla, D.; Quintanilla, M.A.; Lopez-Ayala, J.M.; Facila, L.; Zuazola, P.; Cordero, A.
dc.identifier.doi10.1007/s40256-022-00566-1
dc.identifier.sophos63df0a766fdec82c4e7deaf6
dc.issue.number2
dc.journal.titleAmerican Journal of Cardiovascular Drugs*
dc.organizationServizo Galego de Saúde::Áreas Sanitarias (A.S.) - Instituto de Investigación Sanitaria de Santiago de Compostela (IDIS)
dc.page.initial157
dc.page.final164
dc.relation.projectIDCRUE-CSIC agreement
dc.relation.projectIDSpringer Nature
dc.relation.publisherversionhttps://doi.org/10.1007/s40256-022-00566-1
dc.rights.accessRightsopenAccess*
dc.subject.keywordAS Santiago
dc.subject.keywordIDIS
dc.typefidesArtículo Científico (incluye Original, Original breve, Revisión Sistemática y Meta-análisis)
dc.typesophosArtículo Original
dc.volume.number23


Ficheros en el ítem

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Attribution-NonCommercial 4.0 International (CC BY-NC 4.0)
Excepto si se señala otra cosa, la licencia del ítem se describe como Attribution-NonCommercial 4.0 International (CC BY-NC 4.0)